Pathway Mechanism of Potential Genomic Markers of Dipeptidyl Peptidase-4 Inhibitor Treatment Response in Type 2 Diabetes

被引：0
|
作者：
Jamaluddin, J. L. [1 ]
Huri, H. Z. [1 ]
Vethakkan, S. R. [2 ]
Mustafa, N. [2 ]
Ahmad, W. A. W. [2 ]
机构：
[1] Univ Malaya, Fac Med, Dept Pharm, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Med Ctr, Clin Invest Ctr, Kuala Lumpur 59100, Malaysia
来源：
PUBLIC HEALTH GENOMICS | 2015年 / 18卷
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
P005
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [31] Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review
    Samoilova, Iuliia G.
    Vaizova, Olga E.
    Stankova, Anastasia E.
    Matveeva, Mariia, V
    Podchinenova, Daria, V
    Kudlay, Dmitry A.
    Borozinets, Anastasiia A.
    Filippova, Tatyana A.
    Grishkevich, Ivan R.
    Partala, Anastasia, V
    Gerasimova, Diana A.
    TERAPEVTICHESKII ARKHIV, 2024, 96 (01) : 63 - 67
  • [32] Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis
    Yuichi Terawaki
    Takashi Nomiyama
    Hiroyuki Takahashi
    Yoko Tsutsumi
    Kunitaka Murase
    Ryoko Nagaishi
    Makito Tanabe
    Tadachika Kudo
    Kunihisa Kobayashi
    Tetsuhiko Yasuno
    Hitoshi Nakashima
    Toshihiko Yanase
    Diabetology & Metabolic Syndrome, 7
  • [33] The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes
    Kubota, Yoshiaki
    Miyamoto, Masaaki
    Takagi, Gen
    Ikeda, Takeshi
    Kirinoki-Ichikawa, Sonoko
    Tanaka, Kotoko
    Mizuno, Kyoichi
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2012, 27 (11) : 1364 - 1370
  • [34] Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety
    Deacon, Carolyn F.
    Holst, Jens J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (15) : 2047 - 2058
  • [35] EFFICACY AND SAFETY OF SAXAGLIPTIN, DIPEPTIDYL PEPTIDASE-4 INHIBITOR, IN HEMODIALYSIS PATIENTS WITH TYPE 2 DIABETES
    Abe, M.
    Otsuki, T.
    Maruyama, N.
    Oikawa, O.
    Okada, K.
    NEPHROLOGY, 2016, 21 : 65 - 65
  • [36] Hypoglycemic effect and mechanism of isoquercitrin as an inhibitor of dipeptidyl peptidase-4 in type 2 diabetic mice
    Zhang, Lei
    Zhang, Shi-Tao
    Yin, Yan-Chun
    Xing, Shu
    Li, Wan-Nan
    Fu, Xue-Qi
    RSC ADVANCES, 2018, 8 (27): : 14967 - 14974
  • [37] Association of Dipeptidyl Peptidase-4 Inhibitor Use for Type 2 Diabetes and Incidence of OA in Taiwan
    Lee, Hsiang-Yen
    Chang, Ching-Kuei
    Lin, Tzu-Min
    Ku, Tzu-Tung
    Chen, Jin-Hua
    Chen, Yu-Hsiu
    Chen, Shu-Chuan
    Chang, Chi-Ching
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2347 - 2349
  • [38] EFFECT OF THE DIPEPTIDYL PEPTIDASE-4 INHIBITOR SITAGLIPTIN IN OLDER ADULTS WITH TYPE 2 DIABETES MELLITUS
    Stafford, Sara
    Elahi, Dariush
    Meneilly, Graydon S.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2011, 59 (06) : 1148 - 1149
  • [39] Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes
    Havale, Shrikanth H.
    Pal, Manojit
    BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (05) : 1783 - 1802
  • [40] Cost Effectiveness of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes
    Jinsong Geng
    Hao Yu
    Yiwei Mao
    Peng Zhang
    Yingyao Chen
    PharmacoEconomics, 2015, 33 : 581 - 597
12345